| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making |
0 |
0 |
0 |
36 |
0 |
1 |
4 |
115 |
| 3L, 5L, What the L? A NICE Conundrum |
0 |
0 |
0 |
1 |
1 |
1 |
2 |
38 |
| A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO |
0 |
0 |
0 |
0 |
2 |
3 |
4 |
47 |
| A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE) |
0 |
0 |
0 |
1 |
0 |
1 |
2 |
9 |
| A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? |
0 |
0 |
2 |
6 |
1 |
2 |
8 |
41 |
| A new method for valuing health: directly eliciting personal utility functions |
0 |
0 |
1 |
2 |
0 |
0 |
4 |
19 |
| A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’ |
0 |
0 |
0 |
0 |
2 |
2 |
4 |
5 |
| A note on the nature of utility in time and health and implications for cost utility analysis |
0 |
0 |
2 |
7 |
2 |
2 |
5 |
49 |
| A theoretical framework for TTO valuations of health |
0 |
0 |
0 |
31 |
0 |
0 |
2 |
130 |
| A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach |
0 |
0 |
0 |
32 |
1 |
1 |
1 |
82 |
| A ‘new and improved’ EQ-5D valuation questionnaire? |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
21 |
| All Male Panels and Other Diversity Considerations for ISPOR |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
| An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions |
0 |
0 |
0 |
8 |
0 |
0 |
2 |
71 |
| An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values |
0 |
0 |
6 |
6 |
0 |
2 |
37 |
37 |
| Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) |
0 |
1 |
2 |
2 |
0 |
1 |
3 |
35 |
| Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial |
0 |
0 |
0 |
1 |
1 |
4 |
4 |
20 |
| Comment: Financing New Zealand’s Tertiary Education: How Much Subsidy? |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
5 |
| Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets |
0 |
0 |
0 |
0 |
1 |
1 |
6 |
13 |
| Continuity through change: The rhetoric and reality of health reform in New Zealand |
0 |
0 |
0 |
10 |
0 |
0 |
2 |
43 |
| Correction to: 3L, 5L, What the L? A NICE Conundrum |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
32 |
| Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets |
0 |
0 |
0 |
0 |
0 |
1 |
5 |
13 |
| Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland |
0 |
0 |
0 |
0 |
2 |
2 |
6 |
6 |
| Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis |
0 |
0 |
2 |
134 |
0 |
1 |
9 |
483 |
| EQ-5D and the EuroQol Group: Past, Present and Future |
0 |
0 |
1 |
1 |
1 |
4 |
14 |
32 |
| Getting Health Economics into Practice, Edited by David Kernick. Radcliffe Medical Press, Oxford, 2002. No. of pages: 358. ISBN 1‐85775‐575‐8 |
1 |
1 |
9 |
27 |
2 |
3 |
21 |
105 |
| Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale |
0 |
0 |
0 |
1 |
1 |
1 |
2 |
13 |
| Health care spending and economic output: Granger causality |
0 |
1 |
2 |
232 |
2 |
4 |
8 |
617 |
| INTER‐PROVIDER COMPARISON OF PATIENT‐REPORTED OUTCOMES: DEVELOPING AN ADJUSTMENT TO ACCOUNT FOR DIFFERENCES IN PATIENT CASE MIX |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
10 |
| Identifying the impact of government targets on waiting times in the NHS |
1 |
2 |
4 |
94 |
1 |
3 |
6 |
218 |
| Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
18 |
| International Valuation Protocol for the EQ-5D-Y-3L |
0 |
0 |
0 |
1 |
0 |
2 |
18 |
27 |
| Is there a case for using visual analogue scale valuations in cost‐utility analysis? |
0 |
0 |
0 |
38 |
2 |
2 |
3 |
288 |
| Lead versus lag-time trade-off variants: does it make any difference? |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
30 |
| Local health care expenditure plans and their opportunity costs |
0 |
0 |
1 |
5 |
0 |
0 |
3 |
23 |
| Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffs |
0 |
0 |
2 |
13 |
0 |
0 |
5 |
97 |
| New methods for modelling EQ‐5D‐5L value sets: An application to English data |
0 |
0 |
0 |
0 |
1 |
1 |
10 |
20 |
| One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
20 |
| Operationalizing Value-Based Pricing of Medicines |
0 |
0 |
0 |
8 |
0 |
0 |
4 |
46 |
| Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data |
0 |
0 |
1 |
21 |
0 |
1 |
6 |
68 |
| Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going? |
0 |
3 |
6 |
6 |
2 |
7 |
13 |
17 |
| Searching for cost effectiveness thresholds in the NHS |
0 |
0 |
0 |
19 |
0 |
1 |
10 |
157 |
| TRULY INEFFICIENT OR PROVIDING BETTER QUALITY OF CARE? ANALYSING THE RELATIONSHIP BETWEEN RISK‐ADJUSTED HOSPITAL COSTS AND PATIENTS' HEALTH OUTCOMES |
0 |
0 |
0 |
0 |
1 |
3 |
5 |
70 |
| The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions |
0 |
0 |
0 |
1 |
1 |
1 |
2 |
38 |
| The Purchasing of Health Care by Primary Care Organisations. An evaluation and Guide to Future Policy, by N. Mays, S. Wyke, G. Malbon, N. Goodwin. Open University Press, Buckingham and Philadelphia, 2001. No. of pages: 320. ISBN 0‐335‐20900‐9 |
0 |
0 |
0 |
13 |
1 |
1 |
2 |
78 |
| The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule |
0 |
0 |
1 |
6 |
0 |
0 |
4 |
78 |
| The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand |
0 |
0 |
0 |
22 |
0 |
0 |
1 |
68 |
| The development of new research methods for the valuation of EQ-5D-5L |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
| The effects of denturism: New Zealand dentists' response to competition |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
5 |
| The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
18 |
| The impact of price transparency on consumers and providers: A scoping review |
0 |
1 |
2 |
2 |
2 |
7 |
13 |
14 |
| Time to tweak the TTO: results from a comparison of alternative specifications of the TTO |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
43 |
| Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L |
0 |
0 |
1 |
1 |
0 |
0 |
6 |
22 |
| Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment |
0 |
0 |
0 |
1 |
2 |
2 |
3 |
18 |
| Valuing health‐related quality of life: An EQ‐5D‐5L value set for England |
0 |
0 |
0 |
9 |
0 |
1 |
12 |
65 |
| ‘Is there a case for using visual analogue scale valuations in CUA? Yes there is a case, but what does it add to ordinal data?’ a rejoinder |
0 |
0 |
0 |
8 |
0 |
0 |
2 |
54 |
| Total Journal Articles |
2 |
9 |
45 |
813 |
33 |
70 |
302 |
3,712 |
LogEc is hosted by the
Örebro University School of Business.